Lar tests to reach a definitive integrated diagnosis in most of the cases. This comes with additional cost and higher turnaround time, which is not always affordable in developing countries like India. In addition, the non-uniform distribution of advanced research and diagnostic testing centers adds to the difficulty. Methods: The Indian Society of Neuro-oncology (ISNO) multidisciplinary expert panel consisting of neuropathologists, neurosurgeons, and radiation/medical oncologists convened to prepare the national consensus guidelines for approach to diagnosis of adult diffuse gliomas. Results: Algorithms for arriving at an integrated diagnosis of adult diffuse gliomas predominantly using immunohistochemistry and with minimum possible additional molecular testing were agreed upon, thus addressing the problems of cost, accessibility, and turnaround time. Mandatory and optional tests were proposed for each case scenario. Conclusion: This document represents the consensus of the various neuro-oncology disciplines involved in diagnosis and management of patients with adult diffuse gliomas. The article reflects a practical adaptation of the WHO recommendations to suit a resource constrained setup....
How cell metabolism regulates DNA repair is incompletely understood. Here, we define a GTP-mediated signaling cascade that links metabolism to DNA repair and has significant therapeutic implications. GTP, but not other nucleotides, regulates the activity of Rac1, a guanine nucleotide-binding protein, which promotes the dephosphorylation of serine 323 on Abl-interactor 1 (Abi-1) by protein phosphatase 5 (PP5). Dephosphorylated Abi-1, a protein previously not known to activate DNA repair, promotes nonhomologous end joining. In patients and mouse models of glioblastoma, Rac1 and dephosphorylated Abi-1 mediate DNA repair and resistance to standard-of-care genotoxic treatments. The GTP–Rac1–PP5–Abi-1 signaling axis is not limited to brain cancer, as GTP supplementation promotes DNA repair and Abi-1-S323 dephosphorylation in nonmalignant cells and protects mouse tissues from genotoxic insult. This unexpected ability of GTP to regulate DNA repair independently of deoxynucleotide pools has important implications for normal physiology and cancer treatment. SIGNIFICANCE: A newly described GTP-dependent signaling axis is an unexpected link between nucleotide metabolism and DNA repair. Disrupting this pathway can overcome cancer resistance to genotoxic therapy while augmenting it can mitigate genotoxic injury of normal tissues. This article is featured in Selected Articles from This Issue, p. 5
25 September 2018 in International Journal of Surgical Pathology
Supratentorial ependymomas (ST EPNs) are molecularly characterized, of which the RELA fusion positive tumors are the most common and aggressive subgroup. Moreover, histologically, anaplastic ST EPN (ST-AE) often mimic other central nervous system primary high-grade tumors resulting in a diagnostic dilemma. We aimed to study a cohort of ST-AE; evaluate the expression of two RELA fusion-associated markers—L1CAM and p65 (NF-κB); and correlate their expression with clinical and histological parameters. Cases of ST-AE diagnosed in our department from January 2011 to June 2016 (n = 72) were reviewed. A battery of immunohistochemical markers was employed. A total of 65 confirmed ST-AE were included in the study. Age ranged from 9 months to 60 years. There was a slight predominance in the pediatric population (57%). Male-to-female ratio was 1:1.16. Histomorphological features were varied and mimicked other high-grade tumors in several cases. L1CAM immunopositive tumors constituted 26% of cases and were predominantly seen in young children, in the frontoparietal location, and exhibited clear cell morphology with calcification. A consistent pattern of L1CAM immunopositivity was noted in paired primary and recurrent tumor samples. Our study portrays the varied clinical and histomorphological spectrum of ST-AE. The study emphasizes the association of L1CAM immunopositivity with a wide spectrum of histological parameters, literature on which is scant till date. Since ST EPN-RELA are tumors with aggressive behavior, such a correlation would be clinically relevant, particularly when there is limited access to molecular testing.
Introduction: Recent studies have shown that mitochondrial DNA (mtDNA) content in the tumor tissue is associated with patient survival in glioblastoma (GBM). However, mtDNA content in the blood of patients with GBM and its variation during treatment has not been documented. Hence, we assessed mtDNA content in blood and tumor tissue of GBM patients, its association with survival, and the variation of mtDNA content in blood with treatment. Materials and Methods: GBM tissue obtained from 20 patients, 2 ml blood collected from the same patients at the time of presentation and following radiation therapy (RT), 2 ml blood obtained from 20 healthy volunteers were assessed for mtDNA content using quantitative real-time polymerase chain reaction (comparative ct method). The mtDNA content is expressed as the mtDNA/nuclear gene ratio. Results: The mean mtDNA copy number in the GBM tissue was 492.3819, while in the blood of patients, it was 41.76 ± 19.45. In healthy volunteers' blood, it was 55.97 ± 5.78 (P = 0.04). The median overall survival was 13 months in patients with high tumor mtDNA content and 10 months in patients with low tumor mtDNA content (P = 0.04). Patients with low-mtDNA content in the blood had a relatively higher content in the tumor tissue (correlation coefficient − 0.26; P = 0.27). No significant difference was noted between mtDNA content in preoperative blood (41.76 ± 19.45) and post-RT blood sample (44.16 ± 12.83) (P = 0.6). Conclusion: High GBM tumor mtDNA copy number is associated with better overall survival. mtDNA content in the blood is lower in GBM patients when compared with healthy volunteers. mtDNA content in the blood of the patients did not vary following surgery and RT.